Re: Question for anyone
TGs > 500 market will still exist even if R-IT fails - generic Lovaza is still selling in huge amounts. In reality, R-IT is a cardiovascular trial focused on reducing arterial inflammation and MI/stroke risk in diabetics, only peripherally linked to TGs because when it was designed elevated TGs were still considered a risk factor by FDA (still are by everyone but them). Many of the secondary endpoints are related to measurements of reductions of inflammatory biomarkers in the drug vs. control group - my own blood tests since starting V in 2013 have shown massive reductions in nearly all of them, and I've lost a bunch of inflammatory weight as well. Speaking of which, AMRN recently either filed or received a patent for using V for weight loss - don't have the link for it, but google "Vascepa + obesity" and you should find it.